Results 271 to 280 of about 247,999 (295)
Some of the next articles are maybe not open access.

The future of type 1 cannabinoid receptor allosteric ligands

Drug metabolism reviews (Softcover ed.), 2018
M. Alaverdashvili, R. Laprairie
semanticscholar   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update

Expert Opinion on Therapeutic Patents, 2016
P. Morales   +3 more
semanticscholar   +1 more source

Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor.

Journal of Medicinal Chemistry, 2012
F. Piscitelli   +8 more
semanticscholar   +1 more source

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel   +2 more
exaly  

Breast cancer statistics, 2019

Ca-A Cancer Journal for Clinicians, 2019
Carol E Desantis, Jiemin, Mia M Gaudet
exaly  

Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.

Journal of Medicinal Chemistry, 2015
Shuang Han   +6 more
semanticscholar   +1 more source

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong   +2 more
exaly  

Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.

Journal of Medicinal Chemistry, 2012
S. Pasquini   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy